

Hereditary Central Nervous System Demyelinating Diseases Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/HEE2301ED3F1EN.html>

Date: May 2024

Pages: 139

Price: US\$ 6,499.00 (Single User License)

ID: HEE2301ED3F1EN

Abstracts

The 7 major hereditary central nervous system demyelinating diseases markets are expected to exhibit a CAGR of 9.65% during 2024-2034.

The hereditary central nervous system demyelinating diseases market has been comprehensively analyzed in IMARC's new report titled "Hereditary Central Nervous System Demyelinating Diseases Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Hereditary central nervous system demyelinating diseases (HCNSDD) comprise a group of rare inherited disorders characterized by the progressive loss of myelin, the protective sheath that covers nerve fibers in the central nervous system (CNS). Myelin facilitates efficient nerve signal transmission, and its deterioration results in a range of neurological symptoms. Common indications of HCNSDD encompass a variety of motor and sensory impairments, including muscle weakness, poor coordination, tremors, and difficulty walking. In some cases, cognitive and visual disturbances, as well as speech and swallowing difficulties, may also manifest. Since these diseases have a genetic basis, patients may present with symptoms at different ages, with severity varying from mild to debilitating. Diagnosing HCNSDD involves a combination of clinical evaluation, neuroimaging techniques like magnetic resonance imaging (MRI), and genetic testing. MRI scans often reveal characteristic patterns of demyelination and atrophy within the CNS. Genetic testing identifies mutations in specific genes associated with these disorders, aiding in accurate diagnosis and classification.

The escalating cases of mutations in specific genes, which can affect proteins involved

in myelin production, maintenance, or the regulation of the immune response, are primarily driving the hereditary central nervous system demyelinating diseases market. In addition to this, the inflating utilization of targeted pharmaceutical treatments, including enzyme replacement therapies and immunomodulatory agents, that aim to alleviate symptoms and decelerate the progression of the ailment in patients is also creating a positive outlook for the market. Moreover, the widespread adoption of advanced diagnostic modalities like next-generation sequencing for enhancing the early detection and understanding of these disorders is further bolstering the market growth. Apart from this, the rising usage of rehabilitative measures, such as physical therapy and occupational therapy, is acting as another significant growth-inducing factor. These therapies are crucial in maintaining functional independence and improving the quality of life by focusing on mobility, fine motor skills, and adaptive strategies. Additionally, the increasing research initiatives surrounding gene therapy, since it can help to replace or repair the defective genes that cause the loss of myelin in individuals suffering from HCNSDD, are expected to drive the hereditary central nervous system demyelinating diseases market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the hereditary central nervous system demyelinating diseases market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for hereditary central nervous system demyelinating diseases and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hereditary central nervous system demyelinating diseases market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the hereditary central nervous system demyelinating diseases market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the hereditary central nervous system demyelinating diseases market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current hereditary central nervous system demyelinating diseases marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the hereditary central nervous system demyelinating diseases market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the hereditary central nervous system demyelinating diseases market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the hereditary central nervous system demyelinating diseases market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of hereditary central nervous system demyelinating diseases across the seven major markets?

What is the number of prevalent cases (2018-2034) of hereditary central nervous system demyelinating diseases by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of hereditary central nervous system demyelinating diseases by gender across the seven major markets?

What is the number of prevalent cases (2018-2034) of hereditary central nervous system demyelinating diseases by type across the seven major markets?

How many patients are diagnosed (2018-2034) with hereditary central nervous system demyelinating diseases across the seven major markets?

What is the size of the hereditary central nervous system demyelinating diseases patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of hereditary central nervous system demyelinating diseases?

What will be the growth rate of patients across the seven major markets?

Hereditary Central Nervous System Demyelinating Diseases: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for hereditary central nervous system demyelinating diseases drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the hereditary central nervous system demyelinating diseases market?

What are the key regulatory events related to the hereditary central nervous system demyelinating diseases market?

What is the structure of clinical trial landscape by status related to the hereditary central nervous system demyelinating diseases market?

What is the structure of clinical trial landscape by phase related to the hereditary central nervous system demyelinating diseases market?

What is the structure of clinical trial landscape by route of administration related to the hereditary central nervous system demyelinating diseases market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 HEREDITARY CENTRAL NERVOUS SYSTEM DEMYELINATING DISEASES - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 HEREDITARY CENTRAL NERVOUS SYSTEM DEMYELINATING DISEASES - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 HEREDITARY CENTRAL NERVOUS SYSTEM DEMYELINATING DISEASES -

EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights
- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (2018-2034)
 - 7.2.4 Epidemiology by Gender (2018-2034)
 - 7.2.5 Epidemiology by Type (2018-2034)
 - 7.2.6 Diagnosed Cases (2018-2034)
 - 7.2.7 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (2018-2034)
 - 7.3.4 Epidemiology by Gender (2018-2034)
 - 7.3.5 Epidemiology by Type (2018-2034)
 - 7.3.6 Diagnosed Cases (2018-2034)
 - 7.3.7 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (2018-2034)
 - 7.4.4 Epidemiology by Gender (2018-2034)
 - 7.4.5 Epidemiology by Type (2018-2034)
 - 7.4.6 Diagnosed Cases (2018-2034)
 - 7.4.7 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (2018-2034)
 - 7.5.4 Epidemiology by Gender (2018-2034)
 - 7.5.5 Epidemiology by Type (2018-2034)
 - 7.5.6 Diagnosed Cases (2018-2034)
 - 7.5.7 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (2018-2034)

- 7.6.4 Epidemiology by Gender (2018-2034)
- 7.6.5 Epidemiology by Type (2018-2034)
- 7.6.6 Diagnosed Cases (2018-2034)
- 7.6.7 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)
 - 7.7.3 Epidemiology by Age (2018-2034)
 - 7.7.4 Epidemiology by Gender (2018-2034)
 - 7.7.5 Epidemiology by Type (2018-2034)
 - 7.7.6 Diagnosed Cases (2018-2034)
 - 7.7.7 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (2018-2034)
 - 7.8.4 Epidemiology by Gender (2018-2034)
 - 7.8.5 Epidemiology by Type (2018-2034)
 - 7.8.6 Diagnosed Cases (2018-2034)
 - 7.8.7 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (2018-2034)
 - 7.9.4 Epidemiology by Gender (2018-2034)
 - 7.9.5 Epidemiology by Type (2018-2034)
 - 7.9.6 Diagnosed Cases (2018-2034)
 - 7.9.7 Patient Pool/Treated Cases (2018-2034)

8 HEREDITARY CENTRAL NERVOUS SYSTEM DEMYELINATING DISEASES - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 HEREDITARY CENTRAL NERVOUS SYSTEM DEMYELINATING DISEASES - UNMET NEEDS

10 HEREDITARY CENTRAL NERVOUS SYSTEM DEMYELINATING DISEASES -

KEY ENDPOINTS OF TREATMENT

11 HEREDITARY CENTRAL NERVOUS SYSTEM DEMYELINATING DISEASES - MARKETED PRODUCTS

11.1 List of Hereditary Central Nervous System Demyelinating Diseases Marketed Drugs Across the Top 7 Markets

11.1.1 Libmeldy (Atidarsagene autotemcel) - Orchard Therapeutics

11.1.1.1 Drug Overview

11.1.1.2 Mechanism of Action

11.1.1.3 Regulatory Status

11.1.1.4 Clinical Trial Results

11.1.1.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 HEREDITARY CENTRAL NERVOUS SYSTEM DEMYELINATING DISEASES - PIPELINE DRUGS

12.1 List of Hereditary Central Nervous System Demyelinating Diseases Pipeline Drugs Across the Top 7 Markets

12.1.1 FBX-101 - Forge Biologics

12.1.1.1 Drug Overview

12.1.1.2 Mechanism of Action

12.1.1.3 Clinical Trial Results

12.1.1.4 Safety and Efficacy

12.1.1.5 Regulatory Status

12.1.2 AAV9 BBP-812 - Aspa Therapeutics

12.1.2.1 Drug Overview

12.1.2.2 Mechanism of Action

12.1.2.3 Clinical Trial Results

12.1.2.4 Safety and Efficacy

12.1.2.5 Regulatory Status

12.1.3 rAAV-Olig001-ASPA - Myrtelle

12.1.3.1 Drug Overview

12.1.3.2 Mechanism of Action

12.1.3.3 Clinical Trial Results

12.1.3.4 Safety and Efficacy

12.1.3.5 Regulatory Status

- 12.1.4 ION373 - Ionis Pharmaceuticals
 - 12.1.4.1 Drug Overview
 - 12.1.4.2 Mechanism of Action
 - 12.1.4.3 Clinical Trial Results
 - 12.1.4.4 Safety and Efficacy
 - 12.1.4.5 Regulatory Status
- 12.1.5 Leriglitazone - Minoryx Therapeutics
 - 12.1.5.1 Drug Overview
 - 12.1.5.2 Mechanism of Action
 - 12.1.5.3 Clinical Trial Results
 - 12.1.5.4 Safety and Efficacy
 - 12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. HEREDITARY CENTRAL NERVOUS SYSTEM DEMYELINATING DISEASES - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. HEREDITARY CENTRAL NERVOUS SYSTEM DEMYELINATING DISEASES – CLINICAL TRIAL LANDSCAPE

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

15 HEREDITARY CENTRAL NERVOUS SYSTEM DEMYELINATING DISEASES - MARKET SCENARIO

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
 - 15.2.1 Hereditary Central Nervous System Demyelinating Diseases - Market Size
 - 15.2.1.1 Market Size (2018-2023)
 - 15.2.1.2 Market Forecast (2024-2034)
 - 15.2.2 Hereditary Central Nervous System Demyelinating Diseases - Market Size by Therapies
 - 15.2.2.1 Market Size by Therapies (2018-2023)
 - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States

- 15.3.1 Hereditary Central Nervous System Demyelinating Diseases - Market Size
 - 15.3.1.1 Market Size (2018-2023)
 - 15.3.1.2 Market Forecast (2024-2034)
- 15.3.2 Hereditary Central Nervous System Demyelinating Diseases - Market Size by Therapies
 - 15.3.2.1 Market Size by Therapies (2018-2023)
 - 15.3.2.2 Market Forecast by Therapies (2024-2034)
- 15.3.3 Hereditary Central Nervous System Demyelinating Diseases - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
 - 15.4.1 Hereditary Central Nervous System Demyelinating Diseases - Market Size
 - 15.4.1.1 Market Size (2018-2023)
 - 15.4.1.2 Market Forecast (2024-2034)
 - 15.4.2 Hereditary Central Nervous System Demyelinating Diseases - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (2018-2023)
 - 15.4.2.2 Market Forecast by Therapies (2024-2034)
 - 15.4.3 Hereditary Central Nervous System Demyelinating Diseases - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 Hereditary Central Nervous System Demyelinating Diseases - Market Size
 - 15.5.1.1 Market Size (2018-2023)
 - 15.5.1.2 Market Forecast (2024-2034)
 - 15.5.2 Hereditary Central Nervous System Demyelinating Diseases - Market Size by Therapies
 - 15.5.2.1 Market Size by Therapies (2018-2023)
 - 15.5.2.2 Market Forecast by Therapies (2024-2034)
 - 15.5.3 Hereditary Central Nervous System Demyelinating Diseases - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Hereditary Central Nervous System Demyelinating Diseases - Market Size
 - 15.6.1.1 Market Size (2018-2023)
 - 15.6.1.2 Market Forecast (2024-2034)
 - 15.6.2 Hereditary Central Nervous System Demyelinating Diseases - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
 - 15.6.3 Hereditary Central Nervous System Demyelinating Diseases - Access and Reimbursement Overview

15.7 Market Scenario - Italy

15.7.1 Hereditary Central Nervous System Demyelinating Diseases - Market Size

15.7.1.1 Market Size (2018-2023)

15.7.1.2 Market Forecast (2024-2034)

15.7.2 Hereditary Central Nervous System Demyelinating Diseases - Market Size by Therapies

15.7.2.1 Market Size by Therapies (2018-2023)

15.7.2.2 Market Forecast by Therapies (2024-2034)

15.7.3 Hereditary Central Nervous System Demyelinating Diseases - Access and Reimbursement Overview

15.8 Market Scenario - Spain

15.8.1 Hereditary Central Nervous System Demyelinating Diseases - Market Size

15.8.1.1 Market Size (2018-2023)

15.8.1.2 Market Forecast (2024-2034)

15.8.2 Hereditary Central Nervous System Demyelinating Diseases - Market Size by Therapies

15.8.2.1 Market Size by Therapies (2018-2023)

15.8.2.2 Market Forecast by Therapies (2024-2034)

15.8.3 Hereditary Central Nervous System Demyelinating Diseases - Access and Reimbursement Overview

15.9 Market Scenario - Japan

15.9.1 Hereditary Central Nervous System Demyelinating Diseases - Market Size

15.9.1.1 Market Size (2018-2023)

15.9.1.2 Market Forecast (2024-2034)

15.9.2 Hereditary Central Nervous System Demyelinating Diseases - Market Size by Therapies

15.9.2.1 Market Size by Therapies (2018-2023)

15.9.2.2 Market Forecast by Therapies (2024-2034)

15.9.3 Hereditary Central Nervous System Demyelinating Diseases - Access and Reimbursement Overview

16 HEREDITARY CENTRAL NERVOUS SYSTEM DEMYELINATING DISEASES - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 HEREDITARY CENTRAL NERVOUS SYSTEM DEMYELINATING DISEASES MARKET - SWOT ANALYSIS

17.1 Strengths

17.2 Weaknesses

17.3 Opportunities

17.4 Threats

18 HEREDITARY CENTRAL NERVOUS SYSTEM DEMYELINATING DISEASES MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Hereditary Central Nervous System Demyelinating Diseases Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/HEE2301ED3F1EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/HEE2301ED3F1EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

